Iron Overload
📧 Sign up to get email alerts when something new happens for Iron Overload.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2011-08-11Clinical Trial Update: Safety and Efficacy of Deferasirox in Patients With Transfusion Dependent Iron Overload - a Non-comparative Extension Study [Phase 2, Phase 3]
A non-comparative extension trial assesses safety and efficacy of deferasirox in transfusion-dependent iron overload with liver involvement;…
-
CLINICAL_TRIALS trial_result · 2011-07-29Clinical Trial Update: Extension Study of the Efficacy and Safety of Deferasirox Treatment in Beta-thalassemia Patients With Transfusional Hemosiderosis (Study Amended to 2-year Duration) [Phase 4]
This Phase 4 extension study evaluates the efficacy and safety of deferasirox in transfusion-dependent beta-thalassemia patients with iron o…
-
CLINICAL_TRIALS trial_result · 2011-06-14Clinical Trial Update: Efficacy and Safety of Desferal Versus Osveral in Transfusional Iron Overload [NA]
A completed clinical trial compared the efficacy and safety of the iron chelators deferoxamine (Desferal) and deferasirox (Osveral) for tran…
-
FDA approval · 2011-05-27FDA Approved: DEFEROXAMINE — Supplemental Application (Fresenius Kabi USA, LLC)
FDA approved a supplemental application for deferoxamine mesylate from Fresenius Kabi USA, LLC.
-
CLINICAL_TRIALS trial_result · 2011-05-18Clinical Trial Update: Safety and Efficacy of Deferasirox (ICL670) in Patients With Iron Overload Resulting From Hereditary Hemochromatosis [Phase 1, Phase 2]
Phase 1/2 clinical trials evaluated the safety and efficacy of Deferasirox (ICL670) for iron overload caused by hereditary hemochromatosis, …
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2011-05-02Clinical Trial Update: Study of Deferasirox Relative to Subcutaneous Deferoxamine in Sickle Cell Disease Patients [Phase 2]
Phase 2 trial comparing deferasirox with subcutaneous deferoxamine in patients with sickle cell disease and iron overload; results were post…
-
FDA approval · 2010-09-07FDA Approved: DESFERAL — Supplemental Application (MITEM PHARMA)
The FDA approved a supplemental application for DESFERAL (deferoxamine mesylate) from MITEM PHARMA, indicating regulatory action to modify/e…
-
CLINICAL_TRIALS research · 2010-07-26Clinical Trial Update: Assessment of Iron Deposition in Major Organs of Hemodialysis Patients
An update on a clinical trial assessing iron deposition in major organs of patients undergoing hemodialysis. The current status of the study…
-
CLINICAL_TRIALS research · 2010-05-12Clinical Trial Update: Fetal Parenchymatic Evaluation (Liver, Spleen) Using T2* Sequences
A clinical trial update from Sheba Medical Center investigates fetal liver and spleen parenchymal evaluation using T2* MRI sequences in iron…
-
CLINICAL_TRIALS trial_result · 2010-05-11Clinical Trial Update: MRI Evaluation of Iron Overload in the Heart, Liver and Pancreas in Patients Receiving Multiple Blood Transfusions.
The study completed MRI assessments to evaluate iron deposition in the heart, liver, and pancreas of patients with iron overload receiving r…
-
CLINICAL_TRIALS trial_result · 2010-03-30Clinical Trial Update: Deferasirox in Treating Patients With Iron Overload After Undergoing a Donor Stem Cell Transplant [Phase 2]
Phase 2 trial update on deferasirox for iron overload after donor stem cell transplant; study terminated with results posted in 2010.
-
FDA approval · 2010-01-28FDA Approved: EXJADE — Supplemental Application (Novartis Pharmaceuticals Corporation)
The FDA approved a supplemental application for Exjade (deferasirox) from Novartis Pharmaceuticals Corporation.
-
CLINICAL_TRIALS trial_result · 2010-01-14Clinical Trial Update: Combination Iron Chelation Therapy [Phase 1]
A Phase 1 trial evaluating a combination iron chelation therapy for iron overload and thalassemia has completed.
-
CLINICAL_TRIALS trial_result · 2009-10-21Clinical Trial Update: Therapeutic Effects of Silymarin in Patients With B-thalassemia Major [Phase 2, Phase 3]
A clinical trial update reports on the investigation of silymarin for beta-thalassemia major with iron overload in Phase 2 and Phase 3 studi…
-
CLINICAL_TRIALS trial_result · 2009-09-21Clinical Trial Update: Safety of Various Mode of Delivery of Iron Supplement on Iron Toxicity Markers in Preschool Children [Phase 3]
Phase 3 clinical trial update assessing the safety of different delivery methods for iron supplements on iron toxicity markers in preschool …
-
FDA approval · 2009-09-15FDA Approved: DEFEROXAMINE — Original Application (Fresenius Kabi USA, LLC)
FDA approved Deferoxamine mesylate as a generic product under Original Application by Fresenius Kabi USA, LLC.
-
CLINICAL_TRIALS trial_result · 2009-08-12Clinical Trial Update: Safety and Efficacy of Ferriprox™ (Deferiprone) Oral Solution in Iron Overloaded Pediatric Patients [Phase 3]
Phase 3 trial update reporting safety and efficacy results for Ferriprox (deferiprone) oral solution in iron-overloaded pediatric patients.
-
FDA approval · 2009-04-22FDA Approved: EXJADE — Supplemental Application (Novartis Pharmaceuticals Corporation)
The FDA approved a supplemental application for Exjade (deferasirox) submitted by Novartis Pharmaceuticals Corporation, resulting in changes…
-
CLINICAL_TRIALS trial_result · 2008-03-04Clinical Trial Update: Iron Overload in African Americans
A National Institute of Child Health and Human Development-sponsored clinical trial on iron overload in African Americans has completed.
-
FDA approval · 2007-12-14FDA Approved: DEFEROXAMINE MESYLATE — Supplemental Application (Hospira, Inc.)
FDA approved Hospira's supplemental application for Deferoxamine Mesylate, enabling its continued marketing as an iron chelation therapy.
-
CLINICAL_TRIALS research · 2007-07-12Clinical Trial Update: Study of the Effects of Muscular Activity on Iron Metabolism [NA]
This clinical trial investigates how muscular activity affects iron metabolism. It is sponsored by Rennes University Hospital and lists iron…
-
FDA approval · 2007-04-20FDA Approved: EXJADE — Supplemental Application (Novartis Pharmaceuticals Corporation)
FDA approved a supplemental application for EXJADE (deferasirox) submitted by Novartis Pharmaceuticals Corporation, resulting in an approved…